1 July 2017 - The July 2017 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The July issue of the Schedule includes a number of major new/revised listings:

• Abiraterone acetate (Zytiga) - restriction change
  
• Adalimumab (Humira) - new indication
  
• Dasatinib monohydrate (Sprycel) - restriction change
  
• Degarelix acetate (Firmagon) - restriction change
  
• Pembrolizumab (Keytruda) - new strength
  
• Pirfendone (Esbiet) - new medicine
  
• Vorinostat (Zolinza) - new medicine
  

Read summary of changes